Table 4 |
||||
|
Adverse events |
||||
|
Adverse event |
Any grade |
% |
Grade 3 |
% |
|
|
||||
|
Yellow skin discoloration |
25 |
59 |
- |
- |
|
Fatigue |
24 |
57 |
1 |
2 |
|
Taste changes |
22 |
52 |
- |
- |
|
Mucositits |
21 |
50 |
0 |
0 |
|
Hypertension |
19 |
45 |
7 |
17 |
|
Epigastralgia |
15 |
36 |
0 |
0 |
|
Nausea/vomiting |
14 |
33 |
0 |
0 |
|
Anorexia |
12 |
29 |
2 |
7 |
|
Diarrhea |
11 |
26 |
0 |
0 |
|
Facial edema |
9 |
21 |
1 |
2 |
|
Hand and foot syndrome |
6 |
14 |
0 |
0 |
|
Thyroid function abnormalities |
5 |
12 |
0 |
0 |
|
Thrombopenia |
5 |
12 |
1 |
2 |
|
Anemia |
4 |
10 |
1 |
2 |
|
LVEF reduction* |
3 |
7 |
1 |
2 |
|
Myalgia |
3 |
7 |
0 |
0 |
|
Neutropenia |
3 |
7 |
1 |
2 |
|
Constipation |
2 |
7 |
0 |
0 |
|
Pneumothorax |
1 |
2 |
1 |
2 |
|
Hemoptysis |
2 |
7 |
0 |
0 |
|
|
||||
|
There was one grade 5 adverse event (a patient who developed a massive pulmonary embolism, see text). * Any grade: Reductions in LVEF more than 15% from baseline or LVEF less than 50%. Grade 3: 30–40%. |
||||
|
Kontovinis et al. BMC Cancer 2009 9:82 doi:10.1186/1471-2407-9-82 |
||||
